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Background: The limits of TDF (time, dose, and fractionation) and linear quadratic models
have been known for a long time. Medical physicists and physicians are required to provide
fast and reliable interpretations regarding delivered doses or any future prescriptions relat-
ing to treatment changes.
Aim: We, therefore, propose a calculation interface under the GNU license to be used for
equivalent doses, biological doses, and normal tumor complication probability (Lyman
model).
Materials and methods: The methodology used draws from several sources: the linear-
quadratic-linear model of Astrahan, the repopulation effects of Dale, and the prediction
of  multi-fractionated treatments of Thames.inear quadratic
epopulation
Results and conclusions: The results are obtained from an algorithm that minimizes an ad-
hoc cost function, and then compared to an equivalent dose computed using standard
calculators in seven French radiotherapy centers.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All.  Background:  problems  of  the  biologically
quivalent  dose
t has long been known that radiation biology plays an impor-
ant role and is necessary for radiotherapy treatments. The
ime of radiation effects on normal and malignant tissues
fter exposure range from a femtosecond to months and
ears thereafter.1,2 Therefore, to optimize treatment, it is
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crucial to explain and understand these mechanisms.3–5 Pro-
viding a conceptual basis for radiotherapy and identifying
the mechanisms and processes that underlie the tumor and
normal tissue responses to irradiation can help to explain
the observed phenomena.6 Examples include understanding
hypoxia, reoxygenation, tumor cell repopulation, or the mech-ampus Grimaldi, 20250 Corte, France. Tel.: +33 495293666;
rilvoyant@hotmail.com (C. Voyant).
anisms of repair of DNA damage.3,7,8 The different biological
effects of radiation should be divided into several phases:
the physical phase (interaction between charged particles and
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Nomenclature
˛ and  ˇ ﬁtting parameters of the linear quadratic model
of cell survival (Gy2 and Gy)
˛UNSC adjustment parameter of the occurrence model
of cancer radio-induced (Gy−1)
(x) Heaviside function
/a parameter of the LQL model
 parameter adjustment necessary to take into
account the poly-fractionation in the model LQ
(h−1)
BED biological equivalent dose (Gy)
D physical dose (Gy)
dt dose per fraction from which the curve of cell
survival becomes linear (Gy)
Dprol proliferation dose (Gy/day)
D1 et D2 equivalent doses for the treatments 1 and 2 (Gy)
EQD2 equivalent dose for a 2 Gy/fraction treatment
(Gy)
EUD equivalent uniform dose (Gy)
EUD2Gy EUD for an equivalent dose related to a refer-
ence of 2 Gy per fraction
f cost function to minimize by the algorithm
ja number of day-offs
Hm LQ model correction taking account the poly-
fractionation
Kincidence occurrences probability of radio induced can-
cer (%)
m fraction number and slope factor of the NTCP
model
n number of fraction
NTCP complications rate of post radiation (%)
PUNSC parameter related to the occurrence of
radiation-induced cancers (Gy−1)
T duration between two irradiations (heures)
T overall time (day)
TD50 dose at which there is a 50% complication (Gy)
Tk time at which repopulation begins after start of
treatment (day)
Tpot potential doubling time (day)
Tstop days off during the treatment
results of equivalence (for standard radiotherapy planning).u boundary used in the NCTP calculus (Gy)
tissue atoms), chemical phase (the period during which the
damaged atoms and molecules react with other cellular com-
ponents in rapid chemical reactions), and biological phase
(impact of the generated lesions on the biological tissue4).
The following section describes the models most often used
in radiotherapy. These are simplistic models that actual treat-
ments are based on and that are validated and approved.9–12
1.1.  Reference  models
Numerous models exist to evaluate the biological equiva-
lent dose, but the two most common ones are the nominal
standard dose (NSD13) and linear quadratic (LQ9) models. The
NSD uses the power law described in Eq. (1) (Dtol is the toler-
ance dose of the tissue, NSD is a constant, n and t ∈ R+, N thediotherapy 1 9 ( 2 0 1 4 ) 47–55
number of fractions, and T the overall treatment time). How-
ever, this model has been often criticized.14 In short, some
researchers consider and have even shown that the NSD for-
mula is not a valid description for all tumors and normal
tissues; instead, they maintain that the model incorrectly
describes the effects of fraction number and treatment dura-
tion.
Dtol = NSD · Nn · Tt (1)
The LQ model is most frequently used in radiotherapy
units. It allows the equivalent dose to be easily evaluated for
different fractionations. This concept involves the˛/  ˇ ratio, as
shown in Eq. (2) (D is the total dose for a fraction size of d gray).
EQD2 = D
d + (˛/ˇ)
2 + (˛/ˇ) (2)
EQD2 is the dose obtained using a 2 Gy fraction dose, which
is biologically equivalent to the total dose D given with a frac-
tion dose of d gray. The values of EQD2 may be added in
separate parts in the treatment plan. This formula may be
adapted to fraction doses other than 2 Gy.
1.2.  Limitations  of  the  LQ  model
The LQ model is frequently used for modeling the effects of
radiotherapy at low and medium doses per fraction for which
clinical data appear to ﬁt reasonably well. The main disad-
vantage of the LQ approach is that the overall time factor is
not taken into account, because in radiotherapy it is regarded
to be more  complex than previously supposed.3 It is indeed
very difﬁcult to include this parameter in the LQ equation.
However, a technique may be used to integrate a penalty term
in Eq. (2). Thus, for Tstop days off treatment, the dose recov-
ered would be Tstop·Dprol, where Dprol is the proliferation factor
(in Gy/day; for example, 0.22 for laryngeal edema or 0.15 for
rectosigmoid complications). This methodology is essentially
validated for discontinuation during treatment. As a general
rule, the main limitations of using the LQ model are linked
to repopulation (LQ does not take into account the dose pro-
traction), bi-fractionated treatments and high-dose fractions
(continuously bending survival curve versus linear behavior
observed at least in some cell lines). Other more  sophisticated
models, however, do take into account these weaknesses. We
will later see that the LQ model requires further theoretical
investigation, especially in terms of a biologically effective
dose (BED).
Given the difﬁculty of computing the BED, we  conducted a
study in seven radiotherapy centers in France: CHD Castel-
luccio (Ajaccio; two classical calculators used), Center de
Cancérologie du Grand Montpellier (Montpellier), CRLCC Paul
Lamarque (Montpellier), Clinique Saint-Pierre (Perpignan),
Center de la République (Clermont Ferrand), CHU of Grenoble,
and CHU of Nîmes. A questionnaire was sent to medical physi-
cists working at these centers with the aim of comparing theTable 1 presents the results of this survey which indicate that
not all of the operators obtained the same results. The 95%
conﬁdence interval was often very large. Moreover, the relative
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 47–55 49
Table 1 – Methodologies for computing the equivalent dose used in eight clinical calculators from seven radiotherapy
centers. The median dose, average dose, and standard deviation are given in Gy. For the standard deviation, absolute
and relative modes (/average) were  used. Bold font is used to represent values >5%.
Treatments Organs at risk Target volumes
Spinal cord Prostate (metastasis)
10 × 3 Gy Median  37.50 36.65
Average ± 95% CI 37.8 ± 1.2 36.6 ± 1.9
Stand dev 1.71/4.5% 2.87/7.8%
Spinal cord Breast (metastasis)
10 × 3 Gy Median  37.50 35.57
Average ± 95% CI 37.8 ± 1.2 35.97 ± 1.4
Stand dev 1.71/4.5% 2.06/5.7%
Spinal cord Prostate (metastasis)
1 × 8 Gy Median  20.00 14.90
Average ± 95% CI 19.1 ± 2.3 15.9  ± 3.2
Stand dev 3.38/17.7% 4.72/29.6%
Brain  Breast (metastasis)
10 × 3 Gy Median  37.50 35.57
Average ± 95% CI 37.5 ± 0.9 35.9 ± 1.4
Stand dev 1.26/3.4% 2.03/5.6%
Spinal cord Prostate (metastasis)
1 × 8 Gy (1 month
gap time) 1 × 8 Gy
Median 33.30 21.50
Average ± 95% CI 33.6 ± 4.0 24.04 ± 6.8
Stand dev 5.78/17.2% 9.76/40.6%
Pericardium Lung (metastasis)
5 × 4 Gy Median  30.90 27.07
Average ± 95% CI 33.7 ± 5.9 28.9 ± 3.6
Stand dev 8.47/25.1% 5.14/17.8%
Oral mucosa Oropharynx
20 × 2 Gy (1 week gap
time) 10 × 2 Gy
Median  57.95 57.95
Average ± 95% CI 58.1 ± 0.5 57.6 ± 1.9
Stand dev 0.66/1.14% 2.76/4.8%
Oral mucosa Oropharynx
22 × 1.8 Gy
(bi-fractionated)
Median 41.95 41.70
Average ± 95% CI 41.0 ± 1.6 41.7 ± 2.2
Stand dev 2.32/5.6% 3.12/7.5%
Rectum Prostate
25 × 1.8 Gy then
15 × 2 Gy
Median  72.58 72.75
Average ± 95% CI 72.6 ± 0.4 72.6 ± 0.7
Stand dev 0.54/0.7% 1.00/1.37%
Lung Breast
20 × 2.5 Gy (4
fraction/week)
Median 55.58 53.50
Average ± 95% CI 55.0 ± 1.1 53.5 ± 1.2
Stand dev 1.59/2.9% 1.71/3.2%
Optic chiasma Glioblastoma
4 × 4.5 Gy (2 week
gap time) 4 × 4 Gy
Median 50.25 42.15
Average ± 95% CI 49.9 ± 2.7 43.1 ± 2.8
Stand dev 3.96/7.9% 4.07/9.4%
Skin (early) Breast
28 × 1.8 Gy (1 week
gap time)
Median  46.65 46.36
Average ± 95% CI 46.7 ± 0.6 46.5 ± 0.8
Stand dev 0.90/1.9% 1.13/2.4%
nd ra50  reports of practical oncology a
standard deviation (also known as the dispersion coefﬁcient)
was frequently greater than 5% (13 times out of 24). This dis-
persion was larger in the case of target volumes; the maximal
volume (close to 40%) was related to high doses per fraction
with a gap between two radiotherapy cycles. In Table 1, it is
evident that all of the users did not estimate dose equivalence
in the same manner. Only for a dose per fraction approaching
2 Gy and standard overall time were the results equivalent.
Note that in the multi-fractionated treatments, only 50% of
the centers were able to give an equivalent dose, as this kind
of treatment was not computable.
The numbers of centers included in this study was low, and
there was no consensus among the centers in terms of their
methods for computing the doses. If we  look more  closely,
the biological equivalent dose was the only process that was
calculated using non-ofﬁcial software. All of the other steps
in treatment planning followed an ofﬁcial protocol. It is thus
legitimate to ask why centers use in vivo dosimeters or try
to achieve a global error of 2% throughout treatment, if the
prospective calculation of the equivalent dose (and prescrip-
tion) is greater than 20%. In order to address the question
of responsibility, the following section of this article is tar-
geted at medical physicists, knowing that the prescriber is
the physician. In case of equivalent computations, the optimal
operation would be for the technical work to be performed by
the physicist and validations by the physician (while taking
into account the clinical scenario). This methodology allows
for a double checking of the calculation results.
2.  Aim
We, propose a calculation interface under the GNU license
to be used for equivalent doses, biological doses, and nor-
mal  tumor complication. The next section describes the
theoretical methodology that we propose to compute the
BED.
3.  Materials  and  methods:  the  developed
models
The BED (introduced by Fowler9) is a mathematical concept
used to illustrate the biological effects observed after irradi-
ation. In addition to being easily computable (BED = physical
dose × relative efﬁciency), this notion is interesting because
two irradiations with the same BED generate the same radio-
biological effects. For this reason, it is easy to compare
treatments with different doses, fractionations, and overall
times. The following section introduces the BED-based mod-
els that we  advocate as well as the rules and guidelines for
using the LQL Equiv software.
3.1.  Target  volume  models
Let us examine two different treatment cases separately. The
ﬁrst one involves treatments with a high-dose fraction (one
treatment per day, the fraction size d is greater than the dt
limit15), which requires a linear quadratic linear (LQL) model.
The second case relates to other treatments (d < dt), where the
LQ model is applicable to daily multi-fractionation.16diotherapy 1 9 ( 2 0 1 4 ) 47–55
(a) The d > dt case
When the dose per fraction (d) is greater than the LQL
threshold (dt ∼ 2˛/ˇ), the BED is computed using Eq. (3) (one
fraction permitted per day). This template regroups Astra-
han’s high-dose model17 and Dale’s repopulation model18
(n is the number of fraction, (x) the Heaviside function,
/  ˛ the parameter of the LQL model and Tpot the potential
doubling time in day).
BED = n
(
dt
(
1 + dt
˛/ˇ
)
+ 
˛
(d − dt)
)
− (T − Tk)
ln(2)
 ˛ · Tpot (T − Tk) (3)
The second term used in this equation is useful only when
the overall time T is greater than the Tk value (kick-off
time). If this threshold is not achieved, the tumor is con-
sidered to be non-proliferative (early hypoxia).
(b) The d ≤ dt case
When the fraction dose is low, it is possible to use the
standard BED equations while considering one or more
fractions per day (Eq. (4)). This methodology follows the
model of Thames,19 who introduced the repair factor Hm
related to the amount of unrepaired damage (Eq. (5)). If
the inter-fraction interval is reduced below the full repair
interval (between 6 h and 1 day), the overall damage from
the whole treatment is increased because the repair of
damage due to one radiation dose may not be complete
before the next fraction is given (Hm is LQ model correction
taking into account the poly-fractionation, m the num-
ber of fraction per day,  the incomplete repair and  the
parameter adjustment necessary to take into account the
poly-fractionation in the model LQ in h−1).
BED = n · d
(
1 + (1 + Hm) d
˛/ˇ
)
− (T − Tk)
ln(2)
 ˛ · Tpot(T − Tk)
(4)
Hm =
(
2
m
)(

1 − 
)(
m − 1 − 
m
1 − 
)
and  = e(−T)
(5)
Note that in the case of mono-fractionation, the Hm factor
is null. These equations only relate to the target vol-
ume  calculation. For the organs at risk, the kick-off time
is not relevant, meaning that it is necessary to use a
repopulation-speciﬁc approach.
3.2.  Models  for  organs  at  risk
As in the precedent section on target volumes, this section
similarly separates high and low doses per fraction. The BED
formulae are almost equivalent to the target volume model;
only the terms relating to the lack of dose by proliferation are
modiﬁed.(a) The d > dt case
To understand this methodology, it is necessary to con-
sult Van Dyk’s law.20 The kick-off time is no longer
d rad
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considered, with the recovered dose (Drec = ln(2)/  ˛ · Tpot
in Gy/day) instead being added. The global model is
described in Eq. (6).
BED = n
(
dt
(
1 + dt
˛/ˇ
)
+ 
˛
(d − dt)
)
− DrecT (6)
b) The d ≤ dt case
In the case of low doses per fraction, the methodology is
similar to the target volume model: the Hm parameter (Eq.
(5)) is nonetheless required, which allows us to take into
account more  than one fraction per day. As seen in Eq. (7),
the recovered dose is used as in the previous case.
BED = n · d
(
1 + (1 + Hm) d
˛/ˇ
)
− Drec · T (7)
.3.  Computational  methods  for  the  equivalent  dose
he standard models used for the equivalent dose as based
n the LQ approach are easily exploitable. The main formula-
ion of the model (Eq. (2)) can be obtained by considering the
eneral formula described in Eq. (8) as follows.
1 = D2 (˛/  ˇ + d2)(˛/  ˇ + d1)
(8)
This equation may be validated using the BED methodol-
gy. Considering the BED of two treatments to be equal, it
ppears that a simple relation links the two overall doses,
1(=n1d1) and D2(=n2d2). The detail of this procedure is shown
n Eq. (9).
ED1 = n1 · d1
(
1 + d1
˛/ˇ
)
= BED2 = n2 · d2
(
1 + d2
˛/ˇ
)
(9)
In the case of more  sophisticated BED formulations, it is
ot easy to determine a simple formula linking the D1 and
2 doses, as recovery and repopulation signiﬁcantly compli-
ate the computational principle. Most of the existing software
hat uses the overall time correction does not calculate the
quivalent dose; instead, it only provides the BED for the cho-
en treatments. In clinical use, it is more  valuable for the
hysician or physicist to work with the equivalent dose in
tandard fractionation. In this context, the methodology used
n the LQL Equiv software is based on an innovative algorithm,
hich allows a cost function extremum to be determined
ased on BED modeling. To explain this methodology, it is nec-
ssary to consider two irradiations (Indices 1 and 2), which
re deﬁned by a fraction number (n), dose per fraction (d), and
ays of discontinuation (ja). The corresponding BED is noted as
ED1 (n1, d1, ja1) and BED2 (n2, d2, ja2), while the cost function
 is deﬁned in Eq. (10) as follows.
 (n1, d1, ja1, n2, d2, ja2) = |BED1(n1, d1, ja1) − BED2(n2, d2, ja2)|
(10)In clinical use, it is desirable to compare a radiotherapy trial
ith one that is performed in a conventional manner (gener-
lly with 2 Gy per fraction without interruption). This concept
f a reference dose simpliﬁes the issue, as it is thus possible toiotherapy 1 9 ( 2 0 1 4 ) 47–55 51
dispense with the days off treatment and multi-fractionation
per day in relation to the reference treatment. The following
example concerns a tumor case with a dose per fraction less
than dt (second part of the target volume model), while the
cost function, f, is given in Eq. (11). Concerning the three other
cases examined in the previous sections, a similar relationship
is found.
f (nref, dref, n, d, ja)  = |nref · dref
(
1 + dref
˛/ˇ
)
− (Tref − Tk)
ln(2)
 ˛ · Tpot (Tref − Tk) − n · d
(
1 + (1 + Hm) d
˛/ˇ
)
− (T − Tk)
ln(2)
 ˛ · Tpot (T − Tk)| (11)
The global treatment duration can be seen to be directly
associated with the fraction number and days off during radio-
therapy. Following Eq. (11), the 2 Gy-per-fraction equivalent
dose (EQD2) for standard treatment with the characteristics
is given by the algorithm shown in Eq. (12).
{
argminnref ∈  R+ f (nref, 2, n, d, ja) = n0
EQD2 = 2n0
(12)
All of the results obtained in this section were implemented
using a Matlab® standalone application known as LQL Equiv.
The characteristics of this software, its limitations, and guide-
lines for its use are discussed in the following section.
4.  Results:  LQL  Equiv  software
The LQL Equiv software was developed in collaboration
by the CHD Castelluccio radiotherapy unit in Ajac-
cio and the University of Corsica. It is a free software
released under the GNU license. The source codes, exe-
cutable ﬁle, help ﬁles, and license terms are available at
http://cyril-voyant.univ-corse.fr/LQL-Equiv a34.html. Before
installing this software, it is advisable to refer to the installa-
tion guide and to download and execute Matlab Component
Runtime (MCR 32 bits, version 7.15 or later). This latter step
is necessary since the application was programmed using
the GUI Matlab® software (32 bits, v. 7.12) and deployed with
the Matlab Compiler® (v. 4.12) which use MCR (a standalone
set of shared libraries enabling the execution of Matlab®
applications on a computer without an installed version
of Matlab®). Users of the LQL Equiv software are advised
to provide us with comments on the software, its libraries
(biological parameters for each organ or tumor type), or any
bugs so as to allow us to develop the software. Note that the
application requires Microsoft Windows® (the resolution and
colors are for Vista or later versions).
4.1.  SoftwareThe graphical interface of the LQL Equiv software is pre-
sented in Fig. 1, divided into ﬁve sections: demographical
zone, tissue choice (organs at risk and target volumes), refer-
ence zone (characteristics for computing the equivalent dose),
52  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 47–55
erfacFig. 1 – Graphical int
treatment planning zone (three juxtaposed and independent
treatments), and, ﬁnally, the equivalent dose under the refer-
ence conditions. Prior to using the software, it is important to
understand that repopulation or a high dose per fraction can
considerably alter the standard equivalent results. Therefore,
it is recommended for each user to verify the results obtained
and validate them during an initial test phase. The results
must be consistent with routine procedures as well as the data
in the literature. The details of the instructions allowing to use
the software are available in the Appendix A.
The ideal scenario would be to compare these results with
other softwares and obtain a mean score for the two outputs
or for the outputs that minimize the physical dose. We  rec-
ommend using this software as a secondary BED calculator. It
aims to provide assistance, but cannot be used as a substitute
for routine calculations made by a professional. The creators
of the LQL Equiv software cannot be held responsible for any
errors caused by the misuse of the results obtained.
4.2.  Comparison  with  standard  models
This section compares the results of the LQL Equiv software
with the available clinical models. However, it is important to
note that all of the parameters used for calculating the equiva-
lence are available on the graphical interface. Using MatlabTM
and the downloadable source codes, it is easy to modify or
complete these parameters. It is also possible to contact the
software authors for assistance in developing the software.
LQL Equiv is in direct competition with TDF Plan developed
by Eye Physics LLC, which proposes a multitude of parame-
ters. However, the software is dedicated to the calculation of
BED and is not really consistent with the reference equivalent
dose. Moreover, we aimed to develop ergonomic software with
minimum of adjustable parameters, which ultimately compli-
cate the interpretation of the output. These two approaches
are nevertheless complementary; for more  information about
the different models used, refer to the TDF Plan website
(http://www.eyephysics.com/tdf/Index.htm). Table 2 presents
a comparison between outputs of the standard calculation
models described in section II (LQ without proliferation ande for the LQL Equiv.
˛/  ˇ = 10 for oral mucosa and 2 for others) and the LQL Equiv
software. The difference between the two approaches is sub-
stantial. The overall time effect and unusual doses per fraction
result in completely different outputs. The maximum differ-
ence is close to 25%; this value is linked to the cell repopulation
of prostate cancer. In this case, the non-speciﬁc methods are
certainly not usable.
In addition, for the BED and equivalent calculations,
the LQL Equiv software allows two other parameters to be
obtained, which may be useful in clinical practice: the nor-
mal  tumor complication probability (NTCP22) and the ratio of
radiation-induced cancer after irradiation.
4.3.  Others  elements  computed  by  the  software
In the LQL Equiv software, the bottom of the interface is
dedicated to the calculation of the NTCP and ratio of radiation-
induced cancer. For the ﬁrst parameter, the formula for its
computation (only for normal tissues) is based on the Lyman
model22 as presented in Eq. (12) (TD50 is the dose at which
there is a 50% complication in Gy, u the boundary used in the
NCTP calculus in Gy and m the slope factor). To use this for-
mula, it is necessary to ﬁrst compute the EUD (Niemerko21).
However, in practice, this quantity is not feasible. It is instead
possible to use the equivalent dose related to a reference dose
of 2 Gy per fraction (EQD2 ≈ EUD2Gy). However, the NTCP for-
malism is valid for 2 ± 0.2 Gy/fraction. Moreover, the DVH must
be used, in which case the equivalent dose refers to the aver-
age dose for the parallel organs or the maximal dose (D5%) for
the serial organs.
⎧⎪⎨
⎪⎩
NTCP(n, d, ja) = 1√
2
∫ u
−∞
e−t
2/2dt
u = EUD
2Gy(n, d, ja) − TD50
mTD50
(13)The second add-on in the software concerns the esti-
mation of radiation-induced cancer. The theory used
was developed by the United Nations Scientiﬁc Com-
mittee on the Effects of Atomic Radiation (UNSCEAR;
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 47–55 53
Table 2 – Comparison between the outputs of the LQL Equiv and standard calculation models (LQ without proliferation
and with ˛/  ˇ = 10 for oral mucosa and 2 for others). Bold font is used to show differences >5%.
Treatments Organs at risk Target volumes
Spinal cord Prostate (metastasis)
10 × 3 Gy Classical output (Gy) 37.5 37.5
LQL Equiv output (Gy) 37.5 36
Difference (Gy/%) −0/−0% −1.5/−4%
Spinal cord Breast (metastasis)
10 × 3 Gy Classical output (Gy) 37.5 37.5
LQL Equiv output (Gy) 37.5 38.2
Difference (Gy/%) −0/−0% 0.7/1.9%
Spinal cord Prostate (metastasis)
1 × 8 Gy Classical  output (Gy) 20 20
LQL Equiv output (Gy) 16 16.8
Difference (Gy/%) −4/−20% −3.2/−16%
Brain  Breast (metastasis)
10 × 3 Gy Classical output (Gy) 37.5 37.5
LQL Equiv output (Gy) 43.5 38.2
Difference (Gy/%) 6/16% 0.7/1.9%
Spinal cord Prostate (metastasis)
1 × 8 Gy (1 month
gap time) 1 × 8 Gy
Classical output (Gy)) 40 40
LQL Equiv output (Gy) 32 33.3
Difference (Gy/%) −8/−4.63% −6.7/16.7%
Pericardium Lung (metastasis)
5 × 4 Gy Classical  output (Gy) 30 30
LQL Equiv output (Gy) 37.5 23.3
Difference (Gy/%) 7.5/25% −6.7/−22.3%
Oral mucosa Oropharynx
20 × 2 Gy (1 week gap
time) 10 × 2 Gy
Classical output (Gy) 60 60
LQL Equiv output (Gy) 54.4 53
Difference (Gy/%) −5.6/−9.3% −7/−11.7%
Oral mucosa Oropharynx
22 × 1.8 Gy
(bi-fractionated)
Classical output (Gy) 38.9 38.9
LQL Equiv output (Gy) 45 36
Difference (Gy/%) 6.1/15.7% −2.9/−7.4%
Rectum Prostate
25 × 1.8 Gy then
15 × 2 Gy
Classical output (Gy) 72.7 72.7
LQL Equiv output (Gy) 71 73
Difference (Gy/%) −1.7/−2.3% 0.3/0.4%
Lung Breast
20 × 2.5 Gy (4
fraction/week)
Classical  output (Gy) 56.2 56.2
LQL Equiv output (Gy) 62.9 56.8
Difference (Gy/%) 6.7/11.9% 0.2/0.3%
Optic chiasma Glioblastoma
4 × 4.5 Gy (2 week
gap time) 4 × 4 Gy
Classical output (Gy) 53.2 53.2
LQL Equiv output (Gy) 42.8 47.4
Difference (Gy/%) −10.4/−19.5% −5.8/−10.9%
Skin (early) Breast
28 × 1.8 Gy (1 week
gap time)
Classical output (Gy) 47.9 47.9
LQL Equiv output (Gy) 47.6 42.3
Difference (Gy/%) −0.3/0.6% −5.6/−11.7%
nd ra54  reports of practical oncology a
http://www.unscear.org/unscear/fr/publications.html). The
different meta-analyses of previous radiological incidents
are used in this model. The ratio of radiation-induced cancer
(in %) relating to normal tissue is provided in Eq. (14) as
follows (˛UNSC is the adjustment parameter of the occurrence
model of cancer radio-induced in Gy−1, PUNSC the UNSCEAR
probability and D2Gy the equivalent dose for a 2 Gy/fraction
treatment in Gy).
Kincidence = PUNSC · D2Gy · e−˛UNSC·D
2Gy
(14)
Note that methods used to compute NTCP and Kincidence are
simpliﬁed; it is evident that interested readers must identify
more  specialized documents. These parameters are given as
additional information.
5.  Conclusion
In this article, we  have exposed the compiling results of var-
ious published LQ model modiﬁcations, which have been
modiﬁed to be better suited for specialized radiotherapy tech-
niques such as hypo- or hyperfractionation. The LQ model
was modiﬁed to take into account multi-fractionation, repop-
ulation, high-dose fractions, and overall time. Moreover, we
propose a software program (LQL Equiv), integrating all of
these concepts regarding the main organs at risk or target
volumes. Moreover, this free and easy-to-use software allows
the NTCP to be calculated. Finally, this software permits the
obtained results to be compared and validated against other
“homemade” models, with the purpose of harmonizing prac-
tices in interested centers. However, it is essential not to
consider models as “general biological rules”, parameters and
output uncertainties can be very large; this phenomenon is
related to the number of regression parameters (parsimony
principle) and to the data snooping (e.g. failure to adjust exist-
ing statistical models when applying them to new datasets).
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Appendix  A.  Instructions  for  use
The number of modiﬁable parameters in the LQL Equiv soft-
ware  is minimal, while the items required to complete a dose
equivalent calculation are limited. Only the white boxes can
be modiﬁed.
The upper left part of the interface is dedicated to patient
demography (identity and pathology) and operator traceabil-
ity. These parameters are not essential for initiating the
calculation. Below this, the reference dose per fraction should
be provided; by default, the dose is 2 Gy/fraction.
In the top-right of the interface, there are two dropdown
menus related to the organs at risk and target volumes cho-
sen by the operator to obtain the equivalent dose. Once these
steps are completed, it is necessary to deﬁne the desired treat-
ment plans. Only three plans are proposed, but the software is
able to test more  by integrating the overall results in a single
treatment plan, such as the EQ1 (dose, days off, and number of
fractions must be adjusted). The overall time must be veriﬁed
or else there may be some imprecision in the ﬁnal calcula-
tion. A null number of fractions or doses results in cancelling
the calculation of the equivalent dose (the duration of the
sequence does not contribute to the ﬁnal output).
After selecting the treatment plan and clicking on the cal-
culation button, the BED and equivalent doses are given. The
page may be printed, or otherwise, there is a digital archiving
solution based on the WindowsTM print screen button.
When taking into account the days off, the weekend should
not be considered; only discontinuations that occur dur-
ing weekdays should be included. Beyond 20 days off from
treatment, the algorithms are no longer valid. In the ﬁrst
approximation, the side of caution indicates that healthy tis-
sues do not recover during the gap time. For the second cycle
of radiotherapy that occurs a long time after the ﬁrst one,
we must be vigilant with regard to the treated organs. In the
case of the skin, for example, we  may consider a duration
of 2–5 years to be sufﬁcient to negate any effects from the
previous treatment (this is, however, invalid if the effects are
already visible at the time of irradiation), while for the spinal
cord, it must be considered, where possible, that there exists a
dose memory,  with the effects of gray radiation always being
present. In this regard, the software takes into account that
certain organs, such as spinal cord, have a low Drec in order
to limit the consequences to the most critical organs. More-
over, it is necessary to consider all of the treatment phases if a
dose equivalent is required for the second stage of a prostate
disease. In this case, the ﬁrst phase of the treatment must be
considered, or otherwise, the kick-off time will not be correctly
taken into account.
To avoid the dose overestimation, we recommend ﬁrst cal-
culating the dose equivalent for the organ, i.e., the limiting
factor, and then estimating the fractionation effect on the tar-
get volume.
For organs at risk, it is possible to use the nominal dose.
Thus, in the case of the pelvis, for the ﬁrst 45 Gy given in 25
fractions, the dose received by the rectum may be considered
equal to 45 Gy. However, in order to optimize the methodology,
it seems more  reasonable to utilize a more  detailed analy-
sis. If the validation criterion is D30, the software should be
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ompleted according to the dose per fraction and number of
ractions for the dose received by 30% of the rectum. It is also
ossible to use the average dose for parallel organs, maxi-
al  dose for serial organs, or simply the equivalent uniform
ose (EUD) [21]. Another example illustrating the difference
etween the critical dose and nominal standard dose is based
n spinal irradiation. If doses of 30 Gy in 10 fractions are deliv-
red, this does not necessarily mean that the spinal cord has
eceived the entire dose. Dose volume histogram (DVH) analy-
is allows us to observe that the spinal cord received 32 Gy after
he 10 fractions, which means that the equivalent dose is 10
ractions of 3.2 Gy, which signiﬁcantly changes the results.
Furthermore, it should be added that in this software, as
s often the case, the time between two irradiations in bi-
ractionated radiotherapy must be greater than 6 h.
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